Время | Спикеры | Заголовок сессии | Абстракт | Номер |
16:00 | Part 1 - Market Analysis | 48148 | ||
16:05 | Merger & acquisition trends in medical aesthetics | 48154 | ||
16:17 | New opportunities in the EBD global aesthetic sector | 48156 | ||
16:29 | Global facial aesthetics: disruptors to the market landscape | Посмотреть | 48158 | |
16:45 | Part 2 - Round table lasers and EBD | 48160 | ||
16:45 | Panel industry - Thermi | 48168 | ||
16:45 | Panel industry - Alma Lasers | 48170 | ||
16:45 | Panel industry - Lumenis | 48172 | ||
17:15 | Part 3 - Round table injectables | 48174 | ||
17:15 | Panel industry - Laboratoires Vivacy | 48180 | ||
17:15 | Panel industry - Croma Pharma | 48182 | ||
17:15 | Panel industry - Sinclair Pharma | 48184 | ||
17:15 | Panel industry - Filorga | 48186 | ||
17:50 | Part 4 - Industry strategy | 48190 | ||
17:50 | Zeltiq - Why are non invasive fat reduction and body reshaping procedures today’s fastest growing segment in aesthetics | 48194 | ||
18:00 | Syneron - How to manage the next frontiers of body reshaping | 48166 | ||
18:10 | Merz - Importance of integrating EBD capabilities in combined treatments | 48192 | ||
18:20 | Leveraging Allergan’s R&D to stay at the forefront of the aesthetic market | 48198 | ||
18:30 | Galderma - How to implement a patient-centric strategy | 48196 | ||
18:40 | Teoxane - How to maintain growth in a highly competitive market | 48188 | ||
18:50 | Questions & answers | 48390 | ||